Találati lista | Tudóstér

001-es BibID:	BIBFORM099495
035-os BibID:	(WoS)000763825300031 (Scopus)85122081449
Első szerző:	Keresztes Dávid
Cím:	Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer / Keresztes Dávid, Csizmarik Anita, Nagy Nikolett, Módos Orsolya, Fazekas Tamás, Bracht Thilo, Sitek Barbara, Witzke Kathrin, Puhr Martin, Sevcenco Sabina, Kramer Gero, Shariat Shahrokh, Küronya Zsófia, Takács László, Tornyi Ilona, Lázár József, Hadaschik Boris, Lászik András, Szűcs Miklós, Nyirády Péter, Szarvas Tibor
Dátum:	2022
ISSN:	1582-1838 1582-4934
Megjegyzések:	Baseline or acquired resistance to docetaxel (DOC) represents a significant risk for patients with metastatic prostate cancer (PC). In the last years, novel therapy regimens have been approved providing reasonable alternatives for DOC-resistant patients making prediction of DOC resistance of great clinical importance. We aimed to identify serum biomarkers, which are able to select patients who will not benefit from DOC treatment. DOC-resistant PC3-DR and DU145-DR sublines and their sensitive parental cell lines (DU145, PC3) were comparatively analyzed using liquid chromatography-coupled tandem mass spectrometry (LC-MS/MS). Results were filtered using bioinformatics approaches to identify promising serum biomarkers. Serum levels of five proteins were determined in serum samples of 66 DOC-treated metastatic castration-resistant PC patients (mCRPC) using ELISA. Results were correlated with clinicopathological and survival data. CD44 was subjected to further functional cell culture analyses. We found at least 177 two-fold significantly overexpressed proteins in DOC-resistant cell lines. Our bioinformatics method suggested 11/177 proteins to be secreted into the serum. We determined serum levels of five (CD44, MET, GSN, IL13RA2 and LNPEP) proteins in serum samples of DOC-treated patients and found high CD44 serum levels to be independently associated with poor overall survival (p = 0.001). In accordance, silencing of CD44 in DU145-DR cells resulted in re-sensitization to DOC. In conclusion, high serum CD44 levels may help identify DOC-resistant patients and may thereby help optimize clinical decision-making regarding type and timing of therapy for mCRPC patients. In addition, our in vitro results imply the possible functional involvement of CD44 in DOC resistance.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk biomarker research castration-resistant prostate cancer comparative proteome analysis docetaxel resistance LC-MS/MS
Megjelenés:	Journal Of Cellular And Molecular Medicine. - 26 : 4 (2022), p. 1332-1337. -
További szerzők:	Csizmarik Anita Nagy Nikoletta Módos Orsolya Fazekas Tamás (1950-) (kardiológus) Bracht, Thilo Sitek Barbara Witzke, Kathrin Puhr, Martin Sevcenko, Sabina Kramer, Gero Shariat, Sharokh Küronya Zsófia Takács László (1955-) (orvos) Tornyi Ilona (1982-) (molekuláris biológus) Lázár József Hadaschik, Boris Lászik András Szűcs Miklós (1966-) (urológus, andrológus) Nyirády Péter Szarvas Tibor (matematikus informatikus)
Pályázati támogatás:	FK 124431 NKFIH NVKP_16-1-2016-004 NKFIH ÚNKP-20- 5-SE-1 Egyéb ÚNKP-20-3-II-SE-8 Egyéb
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM115283
035-os BibID:	(cikkazonosító)17378 (Scopus)85174198606
Első szerző:	Váradi Melinda
Cím:	Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice : results of a multicentric, retrospective study / Melinda Váradi, Orsolya Horváth, Orsolya Módos, Tamás Fazekas, Camilla M. Grunewald, Günter Niegisch, Ulrich Krafft, Viktor Grünwald, Boris Hadaschik, Csilla Olah, Anikó Maráz, Andrea Furka, Miklós Szűcs, Péter Nyirády, Tibor Szarvas
Dátum:	2023
ISSN:	2045-2322
Megjegyzések:	Clinical trials revealed significant antitumor activity for immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC). Due to their strict eligibility criteria, clinical trials include selected patient cohorts, and thus do not necessarily represent real-world population outcomes. In this multicentric, retrospective study, we investigated real-world data to assess the effectiveness of pembrolizumab and atezolizumab and to evaluate the prognostic value of routinely available clinicopathological and laboratory parameters. Clinical and follow-up data from mUC patients who received ICIs (01/2017-12/2021) were evaluated. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and duration of response (DOR) were used as endpoints. Patients' (n= 210, n= 76 atezolizumab and 134 pembrolizumab) median OS and PFS were 13.6 and 5.9 months, respectively. Impaired ECOG-PS, the presence of visceral, liver or bone metastases, and hemoglobin levels were independently associated with poor OS and DCR. Furthermore, Bellmunt risk factors and the enhanced Bellmunt-CRP score were shown to be prognostic for OS, PFS and DCR. In conclusion, ICIs are effective treatments for a broad range of mUC patients. Our results confirmed the prognostic value of numerous risk factors and showed that Bellmunt risk scores can further be improved when adding CRP to the model.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk immune checkpoint inhibitor therapy urothelial carcinoma
Megjelenés:	Scientific Reports. - 13 (2023), p. 1-11. -
További szerzők:	Horváth Orsolya Módos Orsolya Fazekas Tamás (1950-) (kardiológus) Grunewald, Camilla M. Niegisch, Günter Krafft, Ulrich Grünwald, Viktor Hadaschik, Boris Oláh Csilla Maráz Anikó Furka Andrea (1976-) (sebész) Szűcs Miklós (1966-) (urológus, andrológus) Nyirády Péter Szarvas Tibor (urológus)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon: